Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Details)

v3.10.0.1
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
segment
Jun. 30, 2017
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment     2  
Segment Reporting Information [Line Items]        
Revenues $ 67,746 $ 62,264 $ 131,169 $ 119,693
Cost of Revenue 37,216 34,912 73,336 69,392
GROSS PROFIT 30,530 27,352 57,833 50,301
General and administrative 20,983 18,432 38,050 35,450
Research and development 1,073 947 2,029 1,809
Sales and marketing 7,680 6,132 14,455 11,779
Total operating expenses 29,736 25,511 54,534 49,038
Income from Operations 794 1,841 3,299 1,263
Interest expense, net (1,407) (1,411) (2,892) (2,775)
Other expense 124 0 62 0
Income (loss) before taxes (737) 430 345 (1,512)
Income tax expense (benefit) (357) (53) 81 (832)
NET INCOME (LOSS) (380) 483 264 (680)
Clinical Services        
Segment Reporting Information [Line Items]        
Revenues 59,540 55,547 116,511 108,455
Cost of Revenue 32,035 30,997 63,076 61,704
GROSS PROFIT 27,505 24,550 53,435 46,751
Pharma Services        
Segment Reporting Information [Line Items]        
Revenues 8,206 6,717 14,658 11,238
Cost of Revenue 5,181 3,915 10,260 7,688
GROSS PROFIT $ 3,025 $ 2,802 $ 4,398 $ 3,550